Roohi Ismail-Khan

5PUBLICATIONS
99CO-AUTHORS
Molecular targetsPredictive and prognostic markersHealth and ecological risk assessmentHaematologyCardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Dec 09, 2024
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer.

Shripad V Bhagwat, Cecilia Mur, Matthew Vandekopple

|Oct 08, 2024
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.

Patrick Neven, Nicole Stahl, Maria Vidal

|Sep 06, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn

|Sep 22, 2023
Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study.

Jamila Mammadova, Christelle Colin-Leitzinger, Diep Nguyen

|Nov 12, 2020
Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils.

Lauren A Baldassarre, Eric H Yang, Richard K Cheng

Pageof 1

Frequent Collaborators

2 joint publications

Philippe Aftimos

2 joint publications

Vanessa Rodrik-Outmezguine

2 joint publications

Bastien Nguyen

2 joint publications

Patrick Neven